Implications of asymptomatic infection for the natural history of selected parasitic tropical diseases

dc.contributor.authorAlvar, Jorge
dc.contributor.authorAlves, Fabiana
dc.contributor.authorBucheton, Bruno
dc.contributor.authorBurrows, Louise
dc.contributor.authorBüscher, Philippe
dc.contributor.authorCarrillo, Eugenia
dc.contributor.authorFelger, Ingrid
dc.contributor.authorHübner, Marc P.
dc.contributor.authorMoreno Blanc, Javier
dc.contributor.authorPinazo, Maria-Jesus
dc.contributor.authorRibeiro, Isabela
dc.contributor.authorSosa Estani, Sergio
dc.contributor.authorSpecht, Sabine
dc.contributor.authorTarral, Antoine
dc.contributor.authorWourgaft, Nathalie Strub
dc.contributor.authorBilbe, Graeme
dc.date.accessioned2020-05-11T11:45:42Z
dc.date.available2020-05-11T11:45:42Z
dc.date.issued2020
dc.date.updated2020-05-08T18:01:33Z
dc.description.abstractProgress has been made in the control or elimination of tropical diseases, with a significant reduction of incidence. However, there is a risk of re-emergence if the factors fueling transmission are not dealt with. Although it is essential to understand these underlying factors for each disease, asymptomatic carriers are a common element that may promote resurgence; their impact in terms of proportion in the population and role in transmission needs to be determined. In this paper, we review the current evidence on whether or not to treat asymptomatic carriers given the relevance of their role in the transmission of a specific disease, the efficacy and toxicity of existing drugs, the Public Health interest, and the benefit at an individual level, for example, in Chagas disease, to prevent irreversible organ damage. In the absence of other control tools such as vaccines, there is a need for safer drugs with good risk/benefit profiles in order to change the paradigm so that it addresses the complete infectious process beyond manifest disease to include treatment of non-symptomatic infected persons.
dc.format.extent16 p.
dc.format.mimetypeapplication/pdf
dc.identifier.issn1863-2297
dc.identifier.pmid32189034
dc.identifier.urihttps://hdl.handle.net/2445/159639
dc.language.isoeng
dc.publisherSpringer
dc.relation.isformatofReproducció del document publicat a: http://dx.doi.org/10.1007/s00281-020-00796-y
dc.relation.ispartofSeminars in Immunopathology, 2020
dc.relation.urihttp://dx.doi.org/10.1007/s00281-020-00796-y
dc.rightscc by (c) Alvar et al., 2020
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/
dc.sourceArticles publicats en revistes (ISGlobal)
dc.subject.classificationMedicina tropical
dc.subject.classificationMalaltia de Chagas
dc.subject.otherTropical medicine
dc.subject.otherChagas' disease
dc.titleImplications of asymptomatic infection for the natural history of selected parasitic tropical diseases
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
Alva_J_Semin_Immunopathol_2020.pdf
Mida:
598.39 KB
Format:
Adobe Portable Document Format